The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: Daina Graybosch - Leerink Partners LLC - Analyst
: Hi. Congratulations on the data. I wonder if you could talk about your dose plans going forward. I noticed in the PK it looks very similar to other
NK cell therapies, where your Cmax sort of declined as you move away from lymphodepletion. Or if you could talk about compressed dosing and
also second cycle dosing. And what situations you would do a second cycle. Thank you.
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
DECEMBER 03, 2024 / 12:30PM, SNTI.OQ - Senti Biosciences Inc Positive Initial Clinical Data in Phase 1 Clinical
Trial of SENTI-202
Question: Daina Graybosch - Leerink Partners LLC - Analyst
: So on the third question, you have flexibility to do that. What kind of data would trigger you to change how frequently you give a dose?
Question: Daina Graybosch - Leerink Partners LLC - Analyst
: Got it. Thank you.
Question: Geulah Livshits - Chardan Capital Markets LLC - Analyst
: Good morning, and congrats on the data, and thanks for taking the questions. I was wondering if there's anything about the patients who did not
respond to therapy that could point to a mechanism, for example, there's CD33 level, FLT3, et cetera or something about the prior treatment. And
then I have a follow-up. Thanks.
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
DECEMBER 03, 2024 / 12:30PM, SNTI.OQ - Senti Biosciences Inc Positive Initial Clinical Data in Phase 1 Clinical
Trial of SENTI-202
Question: Geulah Livshits - Chardan Capital Markets LLC - Analyst
: Got it. Great. Thanks. And just in terms of the logic gate component, you talked about the inhibitory CAR that SENTI-202 contains. What -- I guess,
what kind of signals are you seeing that part is working and talk about obviously the hematologic recovery that you're seeing? What would it look
like if that inhibitory CAR hasn't or wasn't working? In other words, can you talk about the evidence that you're seeing or the proof of concept that
is doing what you expect it to be doing?
Question: Geulah Livshits - Chardan Capital Markets LLC - Analyst
: Fantastic. Thanks. Congrats again.
| 
